title: Milnacipran influences the indexes of I-metaiodobenzylguanidine scintigraphy in elderly depressed patients.
abstract: OBJECTIVE
  This study investigated whether or not and how much milnacipran influences the indexes of I-metaiodobenzylguanidine (I-MIBG) scintigraphy, early heart-to-mediastinum (H/M) ratio, delayed H/M ratio, and wash-out rate.
  
  
  METHODS
  Six elderly depressed patients participated in the study. All six patients met the diagnostic criteria for a major depressive disorder. They were taking milnacipran for their depression. They needed differential diagnosis for Lewy body diseases due to their symptomatology. I-MIBG scintigraphy was performed twice for each subject, once under prescription of milnacipran and the other without prescription of milnacipran.
  
  
  RESULTS
  Both early and delayed phase H/M ratio were significantly lower when taking milnacipran (early phase H/M ratio, P < 0.01, Cohen's d 1.62; delayed phase H/M ratio, P < 0.005, Cohen's d 1.98) than when not taking the drug. Wash-out rate (%) was significantly higher when taking milnacipran (P < 0.05, Cohen's d 2.31) than when off the drug.
  
  
  CONCLUSIONS
  Taking milnacipran substantially influences the indexes of I-MIBG scintigraphy, indicating that taking the drug possibly causes a false-positive result for Lewy body diseases diagnosis.
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Yokoyama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yamada
authors.forename: Sayaka
authors.initials: S
authors.lastname: Terachi
authors.forename: Shenghong
authors.initials: S
authors.lastname: Pu
authors.forename: Yasutoshi
authors.initials: Y
authors.lastname: Ohta
authors.forename: Takehiko
authors.initials: T
authors.lastname: Yamanashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsumura
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Nakagome
authors.forename: Koichi
authors.initials: K
authors.lastname: Kaneko
mesh_terms: D019797:3-Iodobenzylguanidine; D000368:Aged; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects*; D003521:Cyclopropanes / Q000494:pharmacology* / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D020961:Lewy Body Disease / Q000150:complications / Q000000981:diagnostic imaging*; D008297:Male; D000078764:Milnacipran; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals
chemical_list: D000928:Antidepressive Agents; D003521:Cyclopropanes; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; D000078764:Milnacipran